LEXINGTON, Mass., Sept. 21, 2017 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage
biotechnology company devoted to treating inflammation, inborn
errors of metabolism, and other diseases related to endogenous
aldehyde toxicity, today announced the closing of its previously
announced underwritten public offering of 3,967,500 shares of its
common stock, which includes 517,500 shares sold in connection with
the exercise in full by the underwriters of their option to
purchase additional shares. The total net proceeds of the offering
are approximately $26.8 million,
after deducting the underwriting discounts and commissions and
estimated offering expenses payable by Aldeyra.
Cantor Fitzgerald & Co. acted as the sole book-running
manager for the offering. Laidlaw & Company (UK) Ltd.
acted as the lead manager for the offering.
The shares of common stock described above were offered by
Aldeyra pursuant to its shelf registration statement on Form S-3
previously filed with the Securities and Exchange Commission (SEC)
and declared effective by the SEC on September 1, 2015. A final prospectus supplement
and accompanying prospectus relating to and describing the terms of
the offering was filed with the SEC on September 20, 2017 and is available on the SEC's
web site at www.sec.gov. Copies of the final prospectus supplement
and accompanying prospectus relating to these securities may also
be obtained by sending a request to: Cantor Fitzgerald & Co.,
Attention: Capital Markets, 499 Park Avenue, 6th Floor,
New York, New York 10022; e-mail:
prospectus@cantor.com.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to
improving lives by inventing, developing and commercializing
products that treat diseases thought to be related to endogenous
aldehydes, a naturally occurring class of pro-inflammatory and
toxic molecules. Aldeyra's lead product candidate, ADX-102,
is an aldehyde trap in development as topical eye drops for the
treatment of ocular inflammation. ADX-102 has now been tested in
over 250 patients in Phase 2 clinical trials in dry eye disease,
allergic conjunctivitis, and noninfectious anterior uveitis. A
dermatologic form of ADX-102 is in late-stage clinical development
for the treatment of ichthyosis due to Sjögren-Larsson Syndrome, an
inborn error of aldehyde metabolism. ADX-102 has not been approved
for sale in the U.S. or elsewhere.
CONTACT:
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 Ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: +1 339-970-2843
chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
Tel: +1 781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-inc-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option-to-purchase-additional-shares-300524000.html
SOURCE Aldeyra Therapeutics, Inc.